Search research articles
Contact Us
Filters
Showing results (541-550 of 612) with videos related to
Page
of 62
Sort By:
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
The Canadian Journal of Cardiology
|
March 8, 2013
Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?
Hwee Teoh, Jean-Pierre Després, Robert Dufour, et al.
American Heart Journal
|
September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Journal of Clinical Lipidology
|
January 28, 2024
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia
Zobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, et al.
Journal of the American College of Cardiology
|
September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial
Koon K Teo, Steven P Sedlis, William E Boden, et al.
Cancer Immunology Research
|
July 19, 2018
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4<sup>+</sup>Foxp3<sup>-</sup> Cell-Mediated Modulation of CD103<sup>+</sup> Dendritic Cells
Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
JACC. Cardiovascular Imaging
|
March 14, 2024
Comparative Prognostic Utility of Coronary CT and Invasive Angiography: Insights From the ISCHEMIA Trial
Jonathon Leipsic, Sagit Ben Zekry, Georgios Tzimas, et al.
Clinical Chemistry
|
October 18, 2017
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe
Isabelle Ruel, Sumayah Aljenedil, Iman Sadri, et al.
Page
of 62
Search research articles
Search
Showing results (541-550 of 612) with videos related to
Sort By:
Page
of 62
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
The Canadian Journal of Cardiology
|
March 8, 2013
Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?
Hwee Teoh, Jean-Pierre Després, Robert Dufour, et al.
American Heart Journal
|
September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Journal of Clinical Lipidology
|
January 28, 2024
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia
Zobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, et al.
Journal of the American College of Cardiology
|
September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial
Koon K Teo, Steven P Sedlis, William E Boden, et al.
Cancer Immunology Research
|
July 19, 2018
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4<sup>+</sup>Foxp3<sup>-</sup> Cell-Mediated Modulation of CD103<sup>+</sup> Dendritic Cells
Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
JACC. Cardiovascular Imaging
|
March 14, 2024
Comparative Prognostic Utility of Coronary CT and Invasive Angiography: Insights From the ISCHEMIA Trial
Jonathon Leipsic, Sagit Ben Zekry, Georgios Tzimas, et al.
Clinical Chemistry
|
October 18, 2017
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe
Isabelle Ruel, Sumayah Aljenedil, Iman Sadri, et al.
Page
of 62